Navigation Links
Selexis SA Names Dr. Marco Bocci Director of European Sales and Business Development
Date:11/19/2013

Geneva, Switzerland (PRWEB) November 19, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the hire of Marco Bocci, PhD, DPharm, as Director of European Sales and Business Development. Dr. Bocci joins Selexis from Quintiles and will be responsible for growing and managing sales and business development in Europe.

“With the recent launch of our SURE CHO-Mplus Libaries, Selexis is now well positioned to meet our customers biologic development needs from discovery to commercial manufacturing,” said Dr. Igor Fisch, CEO of Selexis SA. “The addition of Marco to our leadership team underscores our commitment to helping our customers discover and commercialize biologic therapeutics. Marco’s knowledge of the CRO field and the scientific skills he acquired at the University of Cambridge are the right fit for our growing technology platform and customer base.”

Dr. Bocci brings a proven track record in business development, sales and clinical development. With over 15 years of experience in life sciences, Dr. Bocci has extensive international business, product development and regulatory knowledge gained within the biotechnology and clinical research industries. Prior to joining Selexis, he was with Quintiles Outcome as Business Development Director where he focused on increasing European market penetration and building new customer relationships. Before joining the industry, Dr. Bocci did his postdoctoral studies at the Medical Research Council (MRC) in Cambridge, UK. He obtained his PhD from the University of Cambridge and is also a trained pharmacist.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/Marco_Bocci_Selexis/cell_line_development/prweb11344577.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
9. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
10. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
11. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: